Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent (NYSE: EVH) will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, followed by a conference call at 8 a.m. ET.
Shareholders can listen via live webcast on Evolent's investor relations website. Analysts may dial the provided US or international numbers and should reference the "Evolent call" 15 minutes prior. An audio replay will be available on the investor site for 90 days.
Evolent (NYSE: EVH) appointed Archie Mayani as chief product officer effective March 19, 2026. Mayani brings more than 20 years of product, AI and health‑tech leadership across GHX, Change Healthcare, Optum/UnitedHealth Group and Amazon.
She has led AI initiatives for supply‑chain resilience, clinical decision support, revenue cycle and population health, and received industry awards in 2023 and 2025.
Foodsmart (EVH) appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors on March 18, 2026. Dr. Ajayi brings value-based care experience focused on Medicaid and dually eligible populations. Foodsmart serves more than 3 million members and aims to embed nutrition into clinical care.
Evolent Health (NYSE: EVH) said members of its executive management team will participate in investor conferences in March 2026, including Cowen on March 3 and Oppenheimer on March 17. A live audio-only webcast and replay will be available in the Events and Presentations section of the company investor relations website.
Presentation webcast times will be posted on the website as they become available.
Evolent Health (NYSE: EVH) reported Q4 2025 revenue of $468.7M and full-year 2025 revenue of $1.876B. GAAP net loss was $429.1M in Q4 and $579.4M for 2025; adjusted EBITDA was $37.8M in Q4 and $151.2M for 2025.
The company ended 2025 with $151.9M cash, projects 2026 revenue of $2.4B–$2.6B, adjusted EBITDA guidance of $110M–$140M, and expects to capitalize $25M–$35M in software development.
Evolent Health (NYSE: EVH) will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026 after market close, followed by a conference call at 5:00 p.m. ET. Participants can listen via the company's investor relations website and analysts may dial in to ask questions. An audio playback will be available on the investor site for 90 days after the call.
Evolent (NYSE: EVH) announced that its Compensation Committee approved a one-time inducement restricted stock unit award of 587,500 shares to Mario Ramos, who became Evolent's Chief Financial Officer effective January 2, 2026. The award was granted under NYSE Listing Rule 303A.08 because Ramos was not a prior employee.
The grant has a grant-date value of $2,350,000 and vests over three years: 34% on the first anniversary, 33% on the second and 33% on the third, contingent on continued employment through each vesting date.
Evolent Health (NYSE: EVH) and American Oncology Network announced a national partnership on Nov 6, 2025 to deploy a quality‑focused cancer care model that aims to reduce costs, speed treatment and remove prior authorization for providers who meet quality standards.
Key elements include gold‑carding providers who adhere to treatment pathways (eliminating most prior authorizations), an AI analytics platform called MiBA for personalized treatment insights, an aligned payment model to reward high‑quality care, and Evolent's care navigation program, Careology. The model will roll out in select markets in the year ahead.
Evolent Health (NYSE: EVH) reported Q3 2025 results: revenue of $479.5M, GAAP net loss of $26.9M and Adjusted EBITDA $38.96M (8.1%). The company added two new customer agreements in Q3, bringing year-to-date new contracts to 13 and now expects to launch more than $750M of new annualized revenue in 2026 with signed contracts preliminarily supporting $2.5B in 2026 revenue. Cash and equivalents were $116.7M at quarter end. Leadership changes include a new CFO, Mario Ramos, and a new Chief Strategy Officer effective Jan 1, 2026. Full-year 2025 guidance is now revenue $1.87B–$1.88B and adjusted EBITDA $144M–$154M. The company reiterated Q4 2025 revenue and adjusted EBITDA ranges.
Evolent (NYSE: EVH) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after market close, followed by a conference call at 5:00 p.m. ET.
Shareholders can listen live and access an audio replay for 90 days on Evolent's investor relations website. Analysts may join the live Q&A via domestic dial-in 855.940.9467 or international 412.317.6034 (reference: "Evolent call").
Management will also present at upcoming investor conferences: UBS Global Healthcare in Palm Beach Gardens on Nov 11, 2025, Stephens Investment in Nashville on Nov 18, 2025, and Piper Sandler Healthcare in New York from Dec 2–4, 2025. Live audio webcasts and replays will be posted in the Events and Presentations section of the investor site as times become available.